Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia

Haematologica. 2022 Oct 1;107(10):2523-2526. doi: 10.3324/haematol.2022.281398.

Authors

Naseema Gangat¹, Jonathan Bleeker², Douglas Lynch², Horatiu Olteanu³, Louis Letendre⁴, Ayalew Tefferi⁴

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN. [email protected].
² Division of Hematology and Hematopathology, Sanford Health, Sioux Falls, SD.
³ Division of Hematopathology, Mayo Clinic, Rochester, MN.
⁴ Division of Hematology, Mayo Clinic, Rochester, MN.

No abstract available

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Red-Cell Aplasia, Pure* / drug therapy

Substances

Antibodies, Monoclonal
daratumumab